Theravance Biopharma (TBPH) Profit After Tax Growth (1y) (2014 - 2026)
Powered by 
Analysis
Theravance Biopharma (TBPH) Profit After Tax Growth (1y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -8.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 92.37% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.21% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 151.28% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 327.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -12.04% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 94.83% |
| 10 | Theravance Biopharma | 882.99 Mn | 495.33 Mn | - | -110.76% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -110.76% |
| Mar 31, 2026 | 63.67% |
| Dec 31, 2025 | 493.02% |
| Sep 30, 2025 | 128.47% |
| Jun 30, 2025 | 431.75% |
| Mar 31, 2025 | -16.42% |
| Dec 31, 2024 | -82.46% |
| Sep 30, 2024 | -41.88% |
| Jun 30, 2024 | -5.65% |
| Mar 31, 2024 | 47.19% |
| Dec 31, 2023 | 40.31% |
| Sep 30, 2023 | -100.98% |
| Jun 30, 2023 | 41.12% |
| Mar 31, 2023 | 46.82% |
| Dec 31, 2022 | 75.34% |
| Sep 30, 2022 | 1,739.48% |
| Jun 30, 2022 | 59.03% |
| Mar 31, 2022 | 51.97% |
| Dec 31, 2021 | 1.06% |
| Sep 30, 2021 | 24.08% |